Bo Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Wen has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Duxin Sun
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, USA
9 shared publications - Lu Wang
Department of Clinical Pharmacy College of Pharmacy University of Michigan Ann Arbor MI USA
8 shared publications - Alexander Ullrich
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
7 shared publications - Alexandra M. O’brien
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
7 shared publications - Ameer L. Elaimy
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
7 shared publications - Andrew J. Scott
University of Michigan
7 shared publications
Latest Publications
- 28 April 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (5) , 857-875
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer
Both regulatory B (Breg) and myeloid cells in tumors and lymph nodes drive immune suppression in pancreatic cancer. Current strategies to counter immune suppression emphasize myeloid cells but overlook Breg cells. We discovered that STING agonist expanded Breg cells depended on PI3Kγ but not PI3Kδ in pancreatic cancer, whereas activating myeloid cells were independent of PI3Kγ. Inhibition of PI3Kγ, but not PI3Kδ, decreased STING-induced IRF3 phosphorylation and Breg cell expansion in pancreatic cancer, while sustaining STING-induced IRF3 phosphorylation to activate myeloid cells. We developed a dual targeting compound and its albumin nanoformulation Nano-273, which stimulated STING to activate myeloid cells and inhibited PI3Kγ to decrease STING-induced Breg cell expansion. Nano-273 delivered the drug to tumors and lymph nodes to overcome myeloid cell- and Breg cell-mediated immune suppression in pancreatic cancer. Nano-273, combined with anti-programmed cell death protein 1, achieved durable efficacy in transgenic KPC mice with pancreatic cancer, offering potential for pancreatic cancer treatment.
- 28 April 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (5) , 857-875
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer
Both regulatory B (Breg) and myeloid cells in tumors and lymph nodes drive immune suppression in pancreatic cancer. Current strategies to counter immune suppression emphasize myeloid cells but overlook Breg cells. We discovered that STING agonist expanded Breg cells depended on PI3Kγ but not PI3Kδ in pancreatic cancer, whereas activating myeloid cells were independent of PI3Kγ. Inhibition of PI3Kγ, but not PI3Kδ, decreased STING-induced IRF3 phosphorylation and Breg cell expansion in pancreatic cancer, while sustaining STING-induced IRF3 phosphorylation to activate myeloid cells. We developed a dual targeting compound and its albumin nanoformulation Nano-273, which stimulated STING to activate myeloid cells and inhibited PI3Kγ to decrease STING-induced Breg cell expansion. Nano-273 delivered the drug to tumors and lymph nodes to overcome myeloid cell- and Breg cell-mediated immune suppression in pancreatic cancer. Nano-273, combined with anti-programmed cell death protein 1, achieved durable efficacy in transgenic KPC mice with pancreatic cancer, offering potential for pancreatic cancer treatment.
- Top Cited Papers
- 18 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (6) , 751-766
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
The protein-protein interaction between menin and KMT2A (histone lysine methyltransferase 2A) plays a critical role in acute leukemia with KMT2A rearrangements, nucleophosmin 1 (NPM1) mutations and nucleoporin 98 rearrangements, and represents an emerging opportunity for therapeutic intervention. Here, we report development and comprehensive evaluation of the activity of ziftomenib as an orally bioavailable, highly potent and selective small molecule inhibitor of the menin-KMT2A interaction. In leukemia cells and primary patient samples with the menin-KMT2A dependency, ziftomenib profoundly inhibited proliferation, reduced clonogenic potential and induced differentiation, which was associated with strong downregulation of the menin-KMT2A target genes, including MEIS1, HOXA9 and HOXB2. In xenografts and patient-derived xenograft models of KMT2A-rearranged leukemia, ziftomenib induced leukemia regression or reduced leukemia burden, accompanied by a pronounced reduction of the menin-KMT2A target genes. We next assessed ziftomenib against four MEN1 (gene encoding menin) mutants (T349M, M327I, G331R, G331D) associated with clinical resistance to another menin inhibitor revumenib. Ziftomenib retained anti-leukemic activity against T349M mutant cells and demonstrated low-nanomolar potency (GI50≤25 nM) against G331R cells, despite several-fold reduced potency relative to MEN1 wild-type cells, whereas M327I and G331D mutants were resistant. The crystal structures of ziftomenib in complex with menin wild-type, T349M or G331R mutants revealed a similar binding mode of ziftomenib to these menin variants, rationalizing potent inhibitory activity towards these mutants. Ziftomenib has recently received FDA approval for adult patients with NPM1-mutated acute myeloid leukemia and continues to be evaluated clinically in leukemias with NPM1 or KMT2A alterations, both as monotherapy and in combinations.
- 18 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (6) , 751-766
Top Cited PapersDiscovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
The protein-protein interaction between menin and KMT2A (histone lysine methyltransferase 2A) plays a critical role in acute leukemia with KMT2A rearrangements, nucleophosmin 1 (NPM1) mutations and nucleoporin 98 rearrangements, and represents an emerging opportunity for therapeutic intervention. Here, we report development and comprehensive evaluation of the activity of ziftomenib as an orally bioavailable, highly potent and selective small molecule inhibitor of the menin-KMT2A interaction. In leukemia cells and primary patient samples with the menin-KMT2A dependency, ziftomenib profoundly inhibited proliferation, reduced clonogenic potential and induced differentiation, which was associated with strong downregulation of the menin-KMT2A target genes, including MEIS1, HOXA9 and HOXB2. In xenografts and patient-derived xenograft models of KMT2A-rearranged leukemia, ziftomenib induced leukemia regression or reduced leukemia burden, accompanied by a pronounced reduction of the menin-KMT2A target genes. We next assessed ziftomenib against four MEN1 (gene encoding menin) mutants (T349M, M327I, G331R, G331D) associated with clinical resistance to another menin inhibitor revumenib. Ziftomenib retained anti-leukemic activity against T349M mutant cells and demonstrated low-nanomolar potency (GI50≤25 nM) against G331R cells, despite several-fold reduced potency relative to MEN1 wild-type cells, whereas M327I and G331D mutants were resistant. The crystal structures of ziftomenib in complex with menin wild-type, T349M or G331R mutants revealed a similar binding mode of ziftomenib to these menin variants, rationalizing potent inhibitory activity towards these mutants. Ziftomenib has recently received FDA approval for adult patients with NPM1-mutated acute myeloid leukemia and continues to be evaluated clinically in leukemias with NPM1 or KMT2A alterations, both as monotherapy and in combinations.
- 1 May 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (5) , 669-671
IDOL Deficiency Inhibits Cholesterol-Rich Diet–Induced Atherosclerosis in Rabbits
- 1 May 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (5) , 669-671
IDOL Deficiency Inhibits Cholesterol-Rich Diet–Induced Atherosclerosis in Rabbits
- 3 February 2025
- Published by Elsevier in Cell Chemical Biology
- Vol. 32 (2) , 280-290.e14
An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment
- 3 February 2025
- Published by Elsevier in Cell Chemical Biology
- Vol. 32 (2) , 280-290.e14
An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment
- 1 November 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (21) , 19010-19037
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Despite the development of highly effective therapies for the treatment of estrogen receptor α (ERα)-positive human breast cancer, clinical resistance to current therapies requires the development of novel therapeutic strategies. Herein, we report the discovery of ERD-1233 as a potent and orally efficacious ERα degrader designed using the PROTAC technology. ERD-1233 was developed based on Lasofoxifene as the ER binding moiety and a novel cereblon ligand through extensive optimization of the linker. ERD-1233 potently and effectively reduces the ERα protein in vitro and achieves excellent oral bioavailability in mice and rats. Oral administration of ERD-1233 effectively reduces ER protein in ER+ tumors and achieves tumor regression in the ER wild-type MCF-7 xenograft tumor model and strong tumor growth inhibition in the ESR1Y537S mutated model in mice. Our data demonstrate that ERD-1233 is a promising ER PROTAC degrader for extensive evaluation as a new therapy for the treatment of ER+ human breast cancer.
- 1 November 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (21) , 19010-19037
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Despite the development of highly effective therapies for the treatment of estrogen receptor α (ERα)-positive human breast cancer, clinical resistance to current therapies requires the development of novel therapeutic strategies. Herein, we report the discovery of ERD-1233 as a potent and orally efficacious ERα degrader designed using the PROTAC technology. ERD-1233 was developed based on Lasofoxifene as the ER binding moiety and a novel cereblon ligand through extensive optimization of the linker. ERD-1233 potently and effectively reduces the ERα protein in vitro and achieves excellent oral bioavailability in mice and rats. Oral administration of ERD-1233 effectively reduces ER protein in ER+ tumors and achieves tumor regression in the ER wild-type MCF-7 xenograft tumor model and strong tumor growth inhibition in the ESR1Y537S mutated model in mice. Our data demonstrate that ERD-1233 is a promising ER PROTAC degrader for extensive evaluation as a new therapy for the treatment of ER+ human breast cancer.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Table S1 shows Supplementary Table S1 and relative references.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Table S1 shows Supplementary Table S1 and relative references.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 2 shows Supplementary Methods, Supplementary Reference, Supplementary Figure S1 and Figure Legends, Supplementary Figure S2 and Figure Legends, Supplementary Figure S3 and Figure Legends, Supplementary Figure S4 and Figure Legends, Supplementary Figure S5 and Figure Legends, Supplementary Figure S6 and Figure Legends, and Supplementary Figure S7 and Figure Legends.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 2 shows Supplementary Methods, Supplementary Reference, Supplementary Figure S1 and Figure Legends, Supplementary Figure S2 and Figure Legends, Supplementary Figure S3 and Figure Legends, Supplementary Figure S4 and Figure Legends, Supplementary Figure S5 and Figure Legends, Supplementary Figure S6 and Figure Legends, and Supplementary Figure S7 and Figure Legends.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 1 shows the original data of phosphoproteomic assay in Figure 2.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 1 shows the original data of phosphoproteomic assay in Figure 2.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 1 shows the original data of phosphoproteomic assay in Figure 2.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 1 shows the original data of phosphoproteomic assay in Figure 2.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 2 shows Supplementary Methods, Supplementary Reference, Supplementary Figure S1 and Figure Legends, Supplementary Figure S2 and Figure Legends, Supplementary Figure S3 and Figure Legends, Supplementary Figure S4 and Figure Legends, Supplementary Figure S5 and Figure Legends, Supplementary Figure S6 and Figure Legends, and Supplementary Figure S7 and Figure Legends.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress
Supplementary Data 2 shows Supplementary Methods, Supplementary Reference, Supplementary Figure S1 and Figure Legends, Supplementary Figure S2 and Figure Legends, Supplementary Figure S3 and Figure Legends, Supplementary Figure S4 and Figure Legends, Supplementary Figure S5 and Figure Legends, Supplementary Figure S6 and Figure Legends, and Supplementary Figure S7 and Figure Legends.